A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Alisertib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Sep 2017 Planned End Date changed from 31 Jul 2018 to 31 Jul 2019.
- 08 Sep 2017 Planned primary completion date changed from 27 Aug 2017 to 27 Aug 2018.
- 24 Jan 2017 Planned End Date changed from 1 Jul 2018 to 31 Jul 2018.